Efficacy and Safety of Sulforaphane for Treatment of Mild to Moderate Depression in Patients With History of Cardiac Interventions: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Efficacy and Safety of Sulforaphane for Treatment of Mild to Moderate Depression in Patients With History of Cardiac Interventions: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Publisher Pubmed

Ghazizadehhashemi F¹ ; Bagheri S² ; Ashrafganjouei A² ; Moradi K² ; Shahmansouri N¹ ; Mehrpooya M³ ; Noorbala AA¹ ; Akhondzadeh S²

Show Affiliations

1. Psychosomatic Research Center, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran
2. Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran
3. Cardiovascular Ward, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Psychiatry and Clinical Neurosciences Published:2021

Abstract

Aim: Depression has been recognized as one of the disorders associated with cardiac interventions such as percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG). In the present study, we evaluated the efficacy and safety of sulforaphane in treatment of depression induced by cardiac interventions. Methods: After initial screening, 66 patients with previous history of at least one cardiac intervention and current mild to moderate depression were randomly assigned to two parallel groups receiving either sulforaphane (n = 33) or placebo (n = 33) for six successive weeks. Efficacy was assessed using the Hamilton Rating Scale for Depression (HAM-D) at baseline and week 2, 4, and 6. Safety of the treatments was checked during the trial period. Results: Sixty participants completed the clinical trial (n = 30 in each group). Baseline demographic and clinical parameters were all similar among groups. Repeated measures analysis indicated that the sulforaphane group exhibited greater improvement in HAM-D scores throughout the trial (P < 0.001). Response to treatment (≥50% reduction in the HAM-D score) rate was higher in the sulforaphane group at trial endpoint (30% vs 6.67%, P = 0.042). Remission (HAM-D score ≤ 7) rate was also higher in the sulforaphane group; however, the difference was not significant (23.33% vs 3.33%, P = 0.052). Finally, no significant difference was observed between the two groups in terms of frequency of side effects. Conclusions: Sulforaphane could safely improve depressive symptoms induced by cardiac interventions. Further clinical trials with larger sample sizes and longer follow-up periods are warranted to confirm our results. © 2021 The Authors Psychiatry and Clinical Neurosciences © 2021 Japanese Society of Psychiatry and Neurology

Related Docs

View other Related Docs

1. Sulforaphane As an Adjunctive Treatment for Irritability in Children With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Psychiatry and Clinical Neurosciences (2020)

2. Emerging Drugs for the Treatment of Irritability Associated With Autism Spectrum Disorder, Expert Opinion on Emerging Drugs (2024)

3. Efficacy and Safety of Tipepidine As Adjunctive Therapy in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Psychiatry and Clinical Neurosciences (2021)

4. Efficacy and Safety of Pentoxifylline Combination Therapy in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, International Clinical Psychopharmacology (2021)

5. The Need for Serious Support for Basic Medical Science in Iran, Avicenna Journal of Medical Biotechnology (2024)

6. Effects of Saffron on Cognition, Anxiety, and Depression in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Double-Blind Placebo-Controlled Trial, Journal of Alternative and Complementary Medicine (2018)

7. Efficacy and Safety of Adjunctive Therapy With Lumateperone in Major Depressive Disorder: A Randomized-, Double-Blind, Placebo-Controlled Clinical Trial, International Clinical Psychopharmacology (2025)

8. Palmitoylethanolamide As Adjunctive Therapy in Major Depressive Disorder: A Double-Blind, Randomized and Placebo-Controlled Trial, Journal of Affective Disorders (2018)

Experts (# of related papers)

View all Related Experts

Shahin Akhondzadeh Basti (20)

Nazila Shahmansouri (4)

Style	Citing Format
MLA	Ghazizadehhashemi F, et al.. "Efficacy and Safety of Sulforaphane for Treatment of Mild to Moderate Depression in Patients With History of Cardiac Interventions: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial." Psychiatry and Clinical Neurosciences, vol. 75, no. 8, 2021, pp. 250-255.
APA	Ghazizadehhashemi F, Bagheri S, Ashrafganjouei A, Moradi K, Shahmansouri N, Mehrpooya M, Noorbala AA, Akhondzadeh S (2021). Efficacy and Safety of Sulforaphane for Treatment of Mild to Moderate Depression in Patients With History of Cardiac Interventions: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Psychiatry and Clinical Neurosciences, 75(8), 250-255.
Chicago	Ghazizadehhashemi F, Bagheri S, Ashrafganjouei A, Moradi K, Shahmansouri N, Mehrpooya M, Noorbala AA, Akhondzadeh S. "Efficacy and Safety of Sulforaphane for Treatment of Mild to Moderate Depression in Patients With History of Cardiac Interventions: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial." Psychiatry and Clinical Neurosciences 75, no. 8 (2021): 250-255.
Harvard	Ghazizadehhashemi F et al. (2021) 'Efficacy and Safety of Sulforaphane for Treatment of Mild to Moderate Depression in Patients With History of Cardiac Interventions: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial', Psychiatry and Clinical Neurosciences, 75(8), pp. 250-255.
Vancouver	Ghazizadehhashemi F, Bagheri S, Ashrafganjouei A, Moradi K, Shahmansouri N, Mehrpooya M, et al.. Efficacy and Safety of Sulforaphane for Treatment of Mild to Moderate Depression in Patients With History of Cardiac Interventions: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Psychiatry and Clinical Neurosciences. 2021;75(8):250-255.
BibTex	@article{ author = {Ghazizadehhashemi F and Bagheri S and Ashrafganjouei A and Moradi K and Shahmansouri N and Mehrpooya M and Noorbala AA and Akhondzadeh S}, title = {Efficacy and Safety of Sulforaphane for Treatment of Mild to Moderate Depression in Patients With History of Cardiac Interventions: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial}, journal = {Psychiatry and Clinical Neurosciences}, volume = {75}, number = {8}, pages = {250-255}, year = {2021} }
RIS	TY - JOUR AU - Ghazizadehhashemi F AU - Bagheri S AU - Ashrafganjouei A AU - Moradi K AU - Shahmansouri N AU - Mehrpooya M AU - Noorbala AA AU - Akhondzadeh S TI - Efficacy and Safety of Sulforaphane for Treatment of Mild to Moderate Depression in Patients With History of Cardiac Interventions: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial JO - Psychiatry and Clinical Neurosciences VL - 75 IS - 8 SP - 250 EP - 255 PY - 2021 ER -

Style

Citing Format

MLA

Ghazizadehhashemi F, et al.. "Efficacy and Safety of Sulforaphane for Treatment of Mild to Moderate Depression in Patients With History of Cardiac Interventions: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial." Psychiatry and Clinical Neurosciences, vol. 75, no. 8, 2021, pp. 250-255.

APA

Ghazizadehhashemi F, Bagheri S, Ashrafganjouei A, Moradi K, Shahmansouri N, Mehrpooya M, Noorbala AA, Akhondzadeh S (2021). Efficacy and Safety of Sulforaphane for Treatment of Mild to Moderate Depression in Patients With History of Cardiac Interventions: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Psychiatry and Clinical Neurosciences, 75(8), 250-255.

Chicago

Ghazizadehhashemi F, Bagheri S, Ashrafganjouei A, Moradi K, Shahmansouri N, Mehrpooya M, Noorbala AA, Akhondzadeh S. "Efficacy and Safety of Sulforaphane for Treatment of Mild to Moderate Depression in Patients With History of Cardiac Interventions: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial." Psychiatry and Clinical Neurosciences 75, no. 8 (2021): 250-255.

Harvard

Ghazizadehhashemi F et al. (2021) 'Efficacy and Safety of Sulforaphane for Treatment of Mild to Moderate Depression in Patients With History of Cardiac Interventions: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial', Psychiatry and Clinical Neurosciences, 75(8), pp. 250-255.

Vancouver

Ghazizadehhashemi F, Bagheri S, Ashrafganjouei A, Moradi K, Shahmansouri N, Mehrpooya M, et al.. Efficacy and Safety of Sulforaphane for Treatment of Mild to Moderate Depression in Patients With History of Cardiac Interventions: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Psychiatry and Clinical Neurosciences. 2021;75(8):250-255.

BibTex

@article{ author = {Ghazizadehhashemi F and Bagheri S and Ashrafganjouei A and Moradi K and Shahmansouri N and Mehrpooya M and Noorbala AA and Akhondzadeh S}, title = {Efficacy and Safety of Sulforaphane for Treatment of Mild to Moderate Depression in Patients With History of Cardiac Interventions: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial}, journal = {Psychiatry and Clinical Neurosciences}, volume = {75}, number = {8}, pages = {250-255}, year = {2021} }

RIS

TY - JOUR
AU - Ghazizadehhashemi F
AU - Bagheri S
AU - Ashrafganjouei A
AU - Moradi K
AU - Shahmansouri N
AU - Mehrpooya M
AU - Noorbala AA
AU - Akhondzadeh S
TI - Efficacy and Safety of Sulforaphane for Treatment of Mild to Moderate Depression in Patients With History of Cardiac Interventions: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
JO - Psychiatry and Clinical Neurosciences
VL - 75
IS - 8
SP - 250
EP - 255
PY - 2021
ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract